Akebia Therapeutics (AKBA) Now Covered by Analysts at Citigroup
Citigroup started coverage on shares of Akebia Therapeutics (NASDAQ:AKBA) in a report published on Wednesday, Marketbeat Ratings reports. The brokerage issued a neutral rating and a $9.00 target price on the biopharmaceutical company’s stock.
A number of other research analysts also recently commented on AKBA. Zacks Investment Research downgraded shares of Akebia Therapeutics from a buy rating to a hold rating in a report on Monday, February 11th. ValuEngine lowered shares of Akebia Therapeutics from a buy rating to a hold rating in a research report on Tuesday, December 18th. Finally, BidaskClub lowered shares of Akebia Therapeutics from a sell rating to a strong sell rating in a research report on Tuesday, December 25th. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the company’s stock. Akebia Therapeutics presently has a consensus rating of Hold and an average price target of $14.28.
Shares of NASDAQ:AKBA opened at $8.62 on Wednesday. Akebia Therapeutics has a 12 month low of $5.20 and a 12 month high of $12.31. The stock has a market capitalization of $462.18 million, a P/E ratio of -4.87 and a beta of 1.46.
About Akebia Therapeutics
Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for patients with renal disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease in dialysis and non-dialysis patients.
Featured Article: Bond
Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.